DC
CPRX

Diametric Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Diametric Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
39,674
+21,187
+115% +$625K 0.13% 170
2026
Q1 		$458K Sell
18,487
-7,966
-30% -$190K 0.12% 239
2025
Q4 		$617K Buy
+26,453
New +$589K 0.17% 180
2024
Q1 		– Sell
-17,336
Closed -$291K – 350
2023
Q4 		$291K Sell
17,336
-14,511
-46% -$198K 0.18% 162
2023
Q3 		$372K Buy
+31,847
New +$426K 0.16% 188
2019
Q3 		– Sell
-50,657
Closed -$195K – 106
2019
Q2 		$195K Buy
+50,657
New +$219K 0.12% 109

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diametric Capital's CPRX Position: Q2 2026 in Review

Diametric Capital increased its Catalyst Pharmaceutical (CPRX) stake by 115% in Q2 2026, buying an estimated $625K and bringing the position to 39,674 shares worth $1.25M. The position accounts for 0.13% of the portfolio, ranked #170.

Diametric Capital first reported a position in CPRX in Q2 2019 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Diametric Capital held 39,674 shares of Catalyst Pharmaceutical worth $1.25M as of Q2 2026.
  • Diametric Capital bought 21,187 Catalyst Pharmaceutical shares in Q2 2026, an estimated $625K.
  • Catalyst Pharmaceutical made up 0.13% of Diametric Capital's portfolio in Q2 2026, its #170 holding.
  • Diametric Capital first reported a position in Catalyst Pharmaceutical in Q2 2019 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.